Serum Institute to make an additional 100 million Covid-19 vaccine doses

Serum Institute of India said on Tuesday it would get a further $150 mn in funding from the Bill & Melinda Gates Foundation and GAVI vaccines alliance to make an additional 100 mn Covid vaccine doses

Serum institute, coronavirus, vaccine, pharma, drugs
Reuters BENGALURU
1 min read Last Updated : Sep 29 2020 | 3:41 PM IST

BENGALURU (Reuters) - Serum Institute of India said on Tuesday it would get a further $150 million in funding from the Bill & Melinda Gates Foundation and the GAVI vaccines alliance to make an additional 100 million COVID-19 vaccine doses for India and other low- and middle-income countries next year.

The collaboration builds upon an initial agreement signed in August by the company with the GAVI alliance and the Gates Foundation, with the total number of vaccine doses to be covered by the partnership now up to 200 million.

 

(Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Shounak Dasgupta)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineSerum Institute of India

First Published: Sep 29 2020 | 3:39 PM IST

Next Story